back to US directory
us clinical guidance

Hepatitis C screening, confirmation and linkage

CDC universal adult and pregnancy screening, antibody-to-RNA confirmation, reinfection testing and linkage to curative treatment.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults, pregnant patients and people of any age with recognized HCV exposure or ongoing risk. Local laboratories should use an antibody test with automatic reflex to nucleic-acid testing whenever possible.
sources for this section:CDC HCV 2020AASLD/IDSA HCV Guidance

The Bottom Line

  • CDC recommends at least one hepatitis C screen for all adults aged 18 years or older and during every pregnancy unless a setting has demonstrated HCV RNA prevalence below 0.1 percent.
  • Test people of any age with recognized exposure or condition and repeat testing while risk continues; one-time universal screening does not replace ongoing-risk testing.
  • Use an HCV-antibody test with reflex HCV RNA to distinguish past exposure from current infection; an antibody-positive, RNA-negative result does not show active viremia at that time.
  • A person with current HCV should be linked promptly to the living AASLD/IDSA treatment pathway because short-course direct-acting antiviral treatment cures most eligible patients and reduces liver harm.
sources for this section:CDC HCV 2020AASLD/IDSA HCV Guidance

Practical clinical workflow

1
Review previous results and treatment, injection or equipment-sharing, transfusion or transplant era, dialysis, incarceration, HIV, pregnancy, occupational exposure and persistently abnormal liver tests without requiring risk disclosure for universal screening.
2
Order antibody with reflex RNA, or HCV RNA directly after recent exposure, suspected acute infection, previous spontaneous clearance or successful treatment when antibody will remain positive.
3
For detectable RNA, assess liver injury and fibrosis, HBV and HIV status, kidney function, pregnancy, medicines and drug interactions, then connect the patient to current AASLD/IDSA simplified or specialist care.
4
Counsel against sharing injection equipment or blood-contaminated personal items, address alcohol and vaccination needs, and plan post-cure RNA testing when reinfection risk continues.
sources for this section:CDC HCV 2020AASLD/IDSA HCV Guidance

Safety boundaries and escalation

  • Jaundice, coagulopathy, encephalopathy, ascites, gastrointestinal bleeding or severe systemic illness requires urgent liver evaluation rather than routine screening follow-up.
  • Do not interpret a reactive antibody as active infection without RNA confirmation, and do not use a negative early antibody to exclude very recent exposure or severe immunosuppression.
  • Before antiviral treatment, assess HBV because reactivation can occur, and reconcile all prescriptions, over-the-counter drugs and supplements for clinically important interactions.
  • Pregnancy, decompensated cirrhosis, previous treatment failure, transplantation or complex comorbidity requires the applicable expert pathway rather than a generic simplified regimen.
sources for this section:CDC HCV 2020AASLD/IDSA HCV Guidance

Localization

US CDC screening is universal, while treatment follows living AASLD/IDSA guidance and may be delivered in primary care. Medicaid restrictions and prior authorization differ by state but should not be confused with clinical eligibility.
sources for this section:CDC HCV 2020AASLD/IDSA HCV Guidance

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Centers for Disease Control and PreventionCDC Recommendations for Hepatitis C Screening Among Adults鈥擴nited States, 2020MMWR 69(2); DOI 10.15585/mmwr.rr6902a1 路 published 2020-04-10 路 accessed 2026-08-20
    view source
  2. American Association for the Study of Liver Diseases and Infectious Diseases Society of AmericaHCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis CLiving guidance checked 2026-08-20 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.